Aligos Therapeutics Inc
ALGSHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 3:59 PM ET
1.98-0.18 (-8.33%)
2026-11-13 13:21 CET
Market cap
$13.96M
Revenue, TTM
33.65 USD m
Net income, TTM
-66.28 USD m
Free cash flow, TTM
-68.66 USD m
EPS diluted, TTM
-6.36
Price
ALGS against its 20, 50 and 200-day averagesPatternshover a marker to name it
85.5% under the 52-week high of 13.69 on 15 Dec 2025. 52-week low 1.92 on 12 Nov 2026. Last 15 sessions, 179.9% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 1 of 6 — fails: EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
ALGS52-week range, 1% of the way up
1.9213.69
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.
| Employees | 82 |
|---|---|
| IPO | Oct 16, 2020 |
| Beta | 2.46 |
| ATR, 14d | 0.53 |
| Rel volume | 0.00 |
| Short float | 12.16% |
| Insider own | 20.98% |
| Inst own | 33.19% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $13.96M |
| Enterprise Value | -5.88M |
| Income | -66.28M |
| Sales | 33.65M |
| Book / share | 1.81 |
| Cash / share | 4.50 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 82 |
| IPO | Oct 16, 2020 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 0.41 |
| Price / book | 1.09 |
| Price / cash | 0.44 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | -0.17 |
| Quick Ratio | 1.77 |
| Current Ratio | 1.77 |
| Debt / equity | 1.05 |
| Long-term debt / equity | 0.94 |
| Options and short | No / Yes |
Earnings
| Earnings / share | -6.36 |
|---|---|
| Earnings next year | -5.65 |
| Earnings next quarter | -2.03 |
| Earnings this year | -174.33% |
| Earnings next year | 15.91% |
| Earnings growth, 5 years | -28.64% |
| Past earnings growth | - - |
| Past sales growth | -46.03% - |
| Earnings vs last year | 49.20% |
| Sales vs last year | 1171.58% |
| Earnings vs last quarter | 31.30% |
| Sales vs last quarter | 287.18% |
| Earnings | Nov 06 BMO |
| Surprise | 8.27% -40.85% |
Ownership
| Insiders own | 20.98% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 33.19% |
| Institution trades | -7.45% |
| Return on assets | -84.46% |
| Return on equity | -159.46% |
| Return on capital | -301.76% |
| Gross Margin | 96.70% |
| Operating margin | -215.55% |
| Profit Margin | -197.01% |
| 20-day average | -54.63% |
| 50-day average | -60.57% |
| 200-day average | -67.21% |
Technical
| Shares out | 7.05M |
|---|---|
| Shares floating | 5.57M |
| Short / float | 12.16% |
| Short ratio | 12.18 |
| Short interest | 0.68M |
| 52-week high | 13.69 -85.5% |
| 52-week low | 1.92 +3.1% |
| Volatility | 30.94% 13.58% |
| Average range | 0.53 |
| Strength index | 18.10 |
| Market sensitivity | 2.46 |
| Relative volume | 0.00 |
| Avg Volume | 55.62K |
| Volume | 0 |
Performance
| Perf Week | -56.10% |
|---|---|
| Perf Month | -62.14% |
| Perf Quarter | -71.26% |
| Perf Half Y | -70.40% |
| Perf YTD | -78.76% |
| Perf Year | -69.33% |
| Perf 3Y | -88.66% |
| Perf 5Y | -99.54% |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 36.88 |
| Prev Close | 1.98 |
| Price | 1.98 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 16| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| May 28, 2026 | Initiated | Lake Street | Buy | $45 | +2,172.7% |
| May 21, 2026 | Initiated | Cantor Fitzgerald | Overweight | $20 | +910.1% |
| Mar 19, 2026 | Resumed | Jefferies | Buy | $48 | +2,324.2% |
| Aug 18, 2025 | Resumed | H.C. Wainwright | Buy | $50 | +2,425.3% |
| Aug 19, 2024 | Initiated | H.C. Wainwright | Buy | $75 | +3,687.9% |
| Jan 06, 2023 | Upgrade | Piper Sandler | Neutral → Overweight | $2 → $3 | +51.5% |
| Jan 06, 2023 | Upgrade | Jefferies | Hold → Buy | $2.50 → $3 | +51.5% |
| Mar 23, 2022 | Downgrade | Piper Sandler | Overweight → Neutral | $15 → $4 | +102.0% |
| Jan 07, 2022 | Downgrade | JP Morgan | Overweight → Neutral | $30 → $12 | +506.1% |
| Jan 06, 2022 | Downgrade | Jefferies | Buy → Hold |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ASMB | Assembly Biosciences Inc | 410.88M |
| ABUS | Arbutus Biopharma Corp | 629.47M |
| VIR | Vir Biotechnology Inc | 1.80B |
| DTIL | Precision Biosciences Inc | 227.99M |
| ENTA | Enanta Pharmaceuticals Inc | 326.20M |
| COCP | Cocrystal Pharma Inc | 19.07M |
| AVIR | Atea Pharmaceuticals Inc | 338.08M |
| NNVC | NanoViricides Inc | 34.46M |
| ALT | Altimmune Inc | 315.12M |
| ARWR | Arrowhead Pharmaceuticals Inc | 6.60B |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| DFMC | U.S. Micro Cap Portfolio ETF Class Shares | AUM: 213.58M |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
| DXUV | US Vector Equity Portfolio ETF Class Shares | AUM: 671.26M |
| DFAC | U.S. Core Equity 2 Portfolio-ETF Class Shares | AUM: 49.67B |
| AVSC | Avantis U.S Small Cap Equity ETF | AUM: 3.33B |
| DFSU | Dimensional US Sustainability Core 1 ETF | AUM: 2.40B |
News
latest 14 of 200- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results (GlobeNewswire) -9.76%
- Aligos Therapeutics Presents Positive Data at The Liver Meeting 2026 (GlobeNewswire) -10.16%
- Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting 2026 (GlobeNewswire)
- Aligos Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
- Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates (InvestorsHub)
- Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China (GlobeNewswire)
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results (GlobeNewswire) +16.24%
- Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
- Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection (GlobeNewswire)
- ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal (Stocktwits)
- Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection (GlobeNewswire)
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 (GlobeNewswire)
- Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 (GlobeNewswire)
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results (GlobeNewswire) -5.34% +6.80%
Quarterly earnings
2026Q3 EPS -2.090 beat -2.279, from -3.040 a year earlier. Sales 2.87 missed 4.85, from 0.74 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-06 08:30 | -2.090 | -2.279 | -2.090 | 2.87 | 4.85 | EPS -8.3% · sales -40.8% | vs 2025Q3, year-ago quarter · EPS -31.3% · sales +287.2% | 8 | Open -1.55% vs SPY +0.25%. Close -9.76% vs SPY +0.31% |
| 2026Q2ended 2026-06-30 | 2026-08-06 08:30 | -0.140 | -1.094 | -0.144 | 27.78 | 24.68 | EPS -87.2% · sales +12.6% | vs 2025Q2, year-ago quarter · EPS -90.8% · sales +2778.5% | 7 EPS · 4 sales | Open -11.81% vs SPY +0.05%. Close +16.24% vs SPY -0.16% |
| 2026Q1ended 2026-03-31 | 2026-05-07 16:30 | -2.210 | -2.213 | -2.215 | 2.83 | 0.25 | EPS -0.1% · sales +1032.0% | vs 2025Q1, year-ago quarter · EPS +4.7% · sales +810.0% | 5 EPS · 4 sales | Open +1.33% vs SPY +0.46%. Close +6.80% vs SPY +0.83% |
| 2025Q4ended 2025-12-31 | 2026-03-05 08:30 | -1.910 | -2.487 | -1.915 | 0.17 | 0.44 | EPS -23.2% · sales -61.6% | vs 2024Q4, year-ago quarter · EPS -85.4% · sales -73.1% | 4 EPS · 5 sales | Open -0.87% vs SPY -0.45%. Close -2.92% vs SPY -0.56% |
| 2025Q3ended 2025-09-30 | 2025-11-06 08:30 | -3.040 | -1.900 | -3.041 | 0.74 | 0.50 | EPS +60.0% · sales +48.2% | vs 2024Q3, year-ago quarter · EPS -1.0% · sales -41.6% | 4 | Open -6.14% vs SPY -0.16%. Close -3.14% vs SPY -1.07% |
| 2025Q2ended 2025-06-30 | 2025-08-06 16:30 | -1.530 | -2.363 | -1.533 | 0.97 | 0.43 | EPS -35.3% · sales +122.7% | vs 2024Q2, year-ago quarter · EPS -304.0% · sales -9.0% | 3 | Open -3.86% vs SPY +0.55%. Close +1.12% vs SPY -0.08% |
| 2025Q1ended 2025-03-31 | 2025-05-06 08:30 | -2.110 | -2.978 | -2.113 | 0.31 | 0.50 | EPS -29.1% · sales -37.8% | vs 2024Q1, year-ago quarter · EPS -61.6% · sales -68.5% | 4 | Open +6.73% vs SPY -0.99%. Close -9.31% vs SPY -0.84% |
| 2024Q4ended 2024-12-31 | 2025-03-10 08:30 | -13.080 | -2.497 | -13.077 | 0.63 | 0.43 | EPS +423.9% · sales +45.2% | vs 2023Q4, year-ago quarter · EPS +137.8% · sales -68.7% | 3 | Open -6.03% vs SPY -1.45%. Close -19.55% vs SPY -2.66% |
| 2024Q3ended 2024-09-30 | 2024-11-06 16:30 | -3.070 | -2.157 | -3.071 | 1.27 | 0.33 | EPS +42.3% · sales +280.7% | vs 2023Q3, year-ago quarter · EPS -70.0% · sales -41.1% | 3 | Open -2.89% vs SPY +0.35%. Close +6.10% vs SPY +0.77% |
| 2024Q2ended 2024-06-30 | 2024-08-06 16:30 | 0.750 | -4.000 | 0.808 | 1.06 | 0.00 | EPS -118.8% · sales - | vs 2023Q2, year-ago quarter · EPS -107.0% · sales -84.6% | 1 | Open +3.98% vs SPY +1.21%. Close +21.95% vs SPY -0.67% |
| 2024Q1ended 2024-03-31 | 2024-05-07 16:30 | -5.500 | -4.750 | -5.582 | 0.99 | 0.00 | EPS +15.8% · sales - | vs 2023Q1, year-ago quarter · EPS -58.5% · sales -63.8% | 2 | Open -0.61% vs SPY -0.36%. Close -0.86% vs SPY +0.01% |
| 2023Q4ended 2023-12-31 | 2024-03-12 16:30 | -5.500 | -7.000 | -5.503 | 2.01 | 1.60 | EPS -21.4% · sales +25.6% | vs 2022Q4, year-ago quarter · EPS -56.9% · sales -43.2% | 2 | Open 0.00% vs SPY +0.06%. Close 0.00% vs SPY -0.16% |
| 2023Q3ended 2023-09-30 | 2023-11-02 16:30 | -10.250 | -11.875 | - | 2.15 | 2.50 | EPS -13.7% · sales -13.8% | vs 2022Q3, year-ago quarter · EPS -6.8% · sales -47.5% | 2 | - |
| 2023Q2ended 2023-06-30 | 2023-08-03 16:30 | -10.750 | -12.375 | - | 6.89 | 0.00 | EPS -13.1% · sales - | vs 2022Q2, year-ago quarter · EPS -8.5% · sales +86.5% | 2 | - |
| 2023Q1ended 2023-03-31 | 2023-05-04 16:30 | -13.250 | -11.833 | - | 2.72 | 0.00 | EPS +12.0% · sales - | vs 2022Q1, year-ago quarter · EPS -36.9% · sales +5.9% | 3 EPS · 2 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-09 16:30 | -12.750 | -12.500 | - | 3.54 | 2.15 | EPS +2.0% · sales +64.5% | vs 2021Q4, year-ago quarter · EPS -42.7% · sales +863.8% | 4 | - |
Annual earnings
2025FY EPS -2.450 beat -9.063, from -20.940 a year earlier. Sales 2.19 missed 2.45, from 3.95 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -5.186 | - | - | 237.27 | - |
| 2029FYestimate | - | -5.320 | - | - | 136.55 | - |
| 2028FYestimate | - | -5.215 | - | - | 54.48 | - |
| 2027FYestimate | - | -5.652 | - | - | 5.41 | - |
| 2026FYestimate | - | -6.721 | - | - | 33.29 | - |
| 2025FY | -2.450 | -9.063 | -2.449 | 2.19 | 2.45 | - |
| 2024FY | -20.940 | -10.093 | -20.945 | 3.95 | 3.73 | - |
| 2023FY | -34.000 | -34.250 | -34.111 | 9.34 | 14.40 | - |
| 2022FY | -56.250 | -53.125 | - | 13.91 | 12.55 | - |
| 2021FY | -80.500 | -78.730 | - | 4.36 | 4.00 | - |
| 2020FY | -216.42 | -76.250 | - | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 2.87, from 0.74 a year earlier. Operating margin -762.72%, from -3,832% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -6.72 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-06 | -6.72 | +2.5% |
| 2026Q4 | E | per share | 2026-11-06 | -2.03 | +5.7% |
| 2026FY | R | per share | 2026-11-06 | -7.12 | +6.1% |
| 2026Q4 | R | per share | 2026-11-06 | -2.26 | -3.0% |
| 2026FY | S | per share | 2026-11-06 | 33.29 | -7.5% |
| 2026Q4 | S | per share | 2026-11-06 | 0.54 | 0.0% |
| 2026Q3 | E | per share | 2026-10-21 | -2.28 | +3.9% |
| 2026Q3 | R | per share | 2026-10-21 | -1.95 | 0.0% |
| 2026Q3 | S | per share | 2026-10-20 | 4.85 | 0.0% |
| 2026Q2 | E | per share | 2026-07-25 | -1.09 | 0.0% |
| 2026Q2 | R | per share | 2026-07-25 | -1.29 | 0.0% |
| 2026Q2 | S | per share | 2026-07-22 | 24.68 | 0.0% |
| 2026Q1 | E | per share | 2026-04-14 | -2.21 | +0.0% |
| 2026Q1 | S | per share | 2026-03-25 | 0.25 | -25.0% |
| 2026Q1 | R | per share | 2026-03-17 | -2.28 | -2.2% |
| 2025FY | R | per share | 2026-03-05 | -6.30 | -13.9% |
| 2025Q4 | R | per share | 2026-03-05 | -2.64 | -2.2% |
| 2025FY | S | per share | 2026-03-05 | 2.21 | -9.7% |
| 2025Q4 | S | per share | 2026-03-05 | 0.20 | -54.5% |
| 2025FY | E | per share | 2026-01-26 | -9.06 | 0.0% |
| 2025Q4 | E | per share | 2026-01-26 | -2.49 | 0.0% |
| 2025Q3 | E | per share | 2025-11-04 | -1.90 | 0.0% |
| 2025Q3 | R | per share | 2025-11-04 | -1.89 | 0.0% |
| 2025Q3 | S | per share | 2025-10-21 | 0.50 | 0.0% |
| 2025Q2 | E | per share | 2025-07-20 | -2.36 | 0.0% |
| 2025Q2 | R | per share | 2025-07-20 | -2.21 | 0.0% |
| 2025Q2 | S | per share | 2025-07-20 | 0.43 | 0.0% |
| 2025Q1 | E | per share | 2025-04-30 | -2.98 | +6.5% |
| 2025Q1 | R | per share | 2025-04-30 | -2.99 | +21.8% |
| 2025Q1 | S | per share | 2025-04-30 | 0.50 | +50.0% |
| 2024FY | E | per share | 2025-01-21 | -10.09 | 0.0% |
| 2024Q4 | E | per share | 2025-01-21 | -2.50 | 0.0% |
| 2024FY | R | per share | 2025-01-21 | -9.56 | 0.0% |
| 2024Q4 | R | per share | 2025-01-21 | -1.99 | 0.0% |
| 2024FY | S | per share | 2025-01-21 | 3.73 | 0.0% |
| 2024Q4 | S | per share | 2025-01-18 | 0.43 | 0.0% |
| 2024Q3 | E | per share | 2024-09-19 | -2.16 | -91.9% |
| 2024Q3 | S | per share | 2024-08-16 | 0.33 | -33.3% |
| 2024Q3 | R | per share | 2024-08-07 | -2.50 | - |
| 2024Q2 | E | per share | 2024-07-22 | -0.16 | 0.0% |
| 2024Q2 | S | per share | 2024-05-30 | 0.00 | - |
| 2024Q1 | E | per share | 2024-03-13 | -0.19 | -51.3% |
| 2024Q1 | S | per share | 2024-03-13 | 0.00 | - |
| 2023FY | E | per share | 2024-02-01 | -1.37 | -1.4% |
| 2023FY | S | per share | 2024-01-17 | 14.40 | 0.0% |
Estimate history
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | - | - | - | - | - | -34.111 | -20.945 | -2.448 | -6.3631 | - |
| Sales USD millions | 0 | 0 | 0 | 4 | 14 | 16 | 4 | 2 | 34 | - |
| Shares million shares | 2 | 2 | 1 | 2 | 2 | 3 | 4 | 6 | - | 6 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -3.071 | -13.077 | -2.113 | -1.533 | -3.041 | -1.915 | -2.215 | -0.144 | -2.09 |
| Sales USD millions | 1 | 1 | 0 | 1 | 1 | 0 | 3 | 28 | 3 |
| Shares million shares | 3 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 33.65 | 2.19-44.4% | 3.94-74.6% | 15.53+11.6% | 13.91+219.0% | 4.36 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 1.11 | 0.93-64.5% | 2.62-14.7% | 3.07-16.3% | 3.67 | - | 3.33+44.8% | 2.30+78.3% | 1.29 |
| Gross Profit | 32.54 | 1.26-4.5% | 1.32-89.4% | 12.46+21.8% | 10.23 | - | -3.33 | -2.30 | -1.29 |
| Selling, General and Administrative Excl. Other | 105.06 | 89.24-1.4% | 90.48-9.4% | 99.89-7.3% | 107.81-16.4% | 128.90+36.4% | 94.51+82.7% | 51.74+318.3% | 12.37 |
| Research and Development | 83.33 | 69.45-1.2% | 70.27-3.8% | 73.04-14.2% | 85.08-18.3% | 104.15+30.4% | 79.89+81.4% | 44.04+321.0% | 10.46 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -72.52 | -87.98 | -89.15 | -87.43 | -97.58 | -128.32 | -97.83 | -54.04 | -13.66 |
| Interest Expense | - | - | - | - | - | - | - | - | 0.27 |
| Unusual Expense | -7.77 | -60.18-230.5% | 46.13+6490.0% | 0.70 | 0.00 | 0.00-100.0% | 11.68 | 0.00 | 0.00 |
| Net Income Before Taxes | -62.80 | -23.88 | -130.88 | -86.88 | -95.94 | -128.19 | -108.38 | -52.18 | -13.93 |
| Income Taxes | 3.48 | 0.31-6.1% | 0.33-58.8% | 0.80+627.3% | 0.11-21.4% | 0.14-12.5% | 0.16+77.8% | 0.09 | 0.00 |
| Consolidated Net Income | -66.28 | -24.19 | -131.21 | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 | -13.93 |
| Net Income From Continuing Operations | -66.28 | -24.19 | -131.21 | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 | -13.93 |
| Net Income | -66.28 | -24.19 | -131.21 | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 | -13.93 |
| EPS (Recurring) per share | -6.86 | -6.71 | -15.79 | -33.92 | - | - | - | - | - |
| EPS (Basic, Before Extraordinaries) per share | -6.36 | -2.45 | -20.94 | -34.11 | - | - | - | - | - |
| EPS (Diluted) per share | -6.36 | -2.45 | -20.94 | -34.11 | - | - | - | - | - |
| EBITDA | -71.41 | -87.06 | -86.53 | -84.36 | -93.91 | -124.54 | -94.51 | -51.74 | -12.37 |
| Non-Operating Income (Expense) | 1.95 | 3.92-11.1% | 4.41+255.6% | 1.24-24.4% | 1.64+1161.5% | 0.13-88.6% | 1.14-38.7% | 1.86 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 4.28 | 3.98-40.4% | 6.68-33.2% | 10.00-13.9% | 11.61+18.2% | 9.82+352.5% | 2.17+294.5% | 0.55+205.6% | 0.18 |
| Price To Sales Ratio ratio | 1.75 | 42.14 | 63.27 | 2.75 | 2.73 | 107.83 | - | - | - |
| Gross Margin % | 96.70 | 57.46 | 33.54 | 80.24 | 73.57 | - | - | - | - |
| Operating Margin % | -215.55 | -4,024.93 | -2,259.92 | -562.99 | -701.66 | -2,943.82 | - | - | - |
| Net Margin % | -197.01 | -1,106.72 | -3,326.01 | -564.61 | -690.63 | -2,944.07 | - | - | - |
| Shares Outstanding million shares | 6.25 | 6.18+60.1% | 3.86+28.7% | 3.00+74.4% | 1.72+0.6% | 1.71+17.1% | 1.46-3.9% | 1.520.0% | 1.52 |
| Market Capitalization | 13.96 | 13.96-90.2% | 142.94+394.8% | 28.89-29.2% | 40.80-91.9% | 506.73-49.9% | 1,012.16+2.2% | 990.68 | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2.87+287.8% | 27.78+2793.8% | 2.83+812.9% | 0.17-73.0% | 0.74-41.7% | 0.96-9.4% | 0.31-68.7% | 0.63-76.5% |
| Cost of Goods Sold Incl. D&A | 0.25+13.6% | 0.260.0% | 0.35+84.2% | 0.26-61.2% | 0.22-67.2% | 0.26-57.4% | 0.19-71.6% | 0.67-14.1% |
| Gross Profit | 2.62+403.8% | 27.52+3776.1% | 2.48+1966.7% | -0.09 | 0.52-13.3% | 0.71+57.8% | 0.12-61.3% | -0.04-102.1% |
| Selling, General and Administrative Excl. Other | 24.51-15.1% | 29.41+52.6% | 29.41+51.9% | 21.73+5.9% | 28.88+39.3% | 19.27-28.3% | 19.36-13.4% | 20.52-26.5% |
| Research and Development | 18.89-21.1% | 24.05+72.0% | 23.35+61.0% | 17.04+6.3% | 23.94+42.8% | 13.98-33.7% | 14.50-11.4% | 16.03-28.0% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -21.89 | -1.89 | -26.93 | -21.81 | -28.36 | -18.57 | -19.24 | -20.56 |
| Unusual Expense | -0.19-104.5% | -2.98 | -3.40 | -1.21-102.6% | 4.21 | -1.68 | -61.49 | 46.13 |
| Net Income Before Taxes | -21.53 | 1.31 | -22.72-152.7% | -19.85 | -31.48 | -15.68-398.7% | 43.13 | -82.12 |
| Income Taxes | 0.33+450.0% | 2.81+1461.1% | 0.32+700.0% | 0.030.0% | 0.06-33.3% | 0.18-5.3% | 0.04+100.0% | 0.03 |
| Consolidated Net Income | -21.86 | -1.50 | -23.04-153.5% | -19.88 | -31.54 | -15.86-413.4% | 43.09 | -82.15 |
| Net Income From Continuing Operations | -21.86 | -1.50 | -23.04-153.5% | -19.88 | -31.54 | -15.86-413.4% | 43.09 | -82.15 |
| Net Income | -21.86 | -1.50 | -23.04-153.5% | -19.88 | -31.54 | -15.86-413.4% | 43.09 | -82.15 |
| EPS (Recurring) per share | -2.10 | -0.34 | -2.44 | -2.00 | -2.76 | -1.65-303.7% | -7.06 | -7.94 |
| EPS (Basic, Before Extraordinaries) per share | -2.09 | -0.14 | -2.21-143.2% | -1.91 | -3.04 | -1.53-288.9% | 5.12 | -13.08 |
| EPS (Diluted) per share | -2.09 | -0.14 | -2.21 | -1.91 | -3.04 | -1.53-288.9% | -2.11 | -13.08 |
| EBITDA | -21.64 | -1.64 | -26.58 | -21.56 | -28.14 | -18.31 | -19.05 | -19.89 |
| Non-Operating Income (Expense) | 0.17-84.3% | 0.22-81.8% | 0.81-8.0% | 0.75 | 1.08+12.5% | 1.21-96.2% | 0.88 | -15.43 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.01-12.9% | 1.08+17.4% | 1.04+36.8% | 1.15-14.8% | 1.16-28.0% | 0.92-43.2% | 0.76-63.6% | 1.35-33.8% |
| Price To Sales Ratio ratio | 1.75 | 1.91 | 16.43 | 44.27 | 38.41 | 23.51 | 21.97 | 63.44 |
| Gross Margin % | 91.25 | 99.08 | 87.77 | -52.07 | 70.31 | 73.16 | 37.62 | -6.68 |
| Operating Margin % | -762.98 | -6.80 | -951.55 | -12,907.69 | -3,827.40 | -1,924.04 | -6,187.46 | -3,269.16 |
| Net Margin % | -761.94 | -5.41 | -814.13 | -11,763.91 | -4,256.01 | -1,643.83 | 13,854.66 | -13,060.41 |
| Shares Outstanding million shares | 6.25+1.6% | 6.24+1.5% | 6.19+1.3% | 6.18+60.1% | 6.15+85.2% | 6.15+92.8% | 6.11+101.7% | 3.86+28.7% |
| Market Capitalization | 13.96-76.8% | 35.71-19.0% | 45.98-8.8% | 57.35-59.9% | 60.28+117.8% | 44.09+66.5% | 50.44-31.5% | 142.94+394.8% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 77.95+36.6% | 57.05-58.0% | 135.77+7.8% | 125.94-34.0% | 190.90-21.8% | 244.07+106.5% | 118.20+29.4% | 91.36 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 4.91-3.5% | 5.09-4.1% | 5.31-30.1% | 7.60-43.8% | 13.53+127.8% | 5.94+194.1% | 2.02+102.0% | 1.00 |
| Total Current Assets | 82.86+33.3% | 62.14-56.0% | 141.08+5.6% | 133.54-34.7% | 204.42-18.2% | 250.02+108.0% | 120.23+30.2% | 92.37 |
| Net Property, Plant & Equipment | 4.96-32.3% | 7.33-25.4% | 9.82-21.5% | 12.51-16.4% | 14.97+0.4% | 14.91-7.3% | 16.09+6.0% | 15.18 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 15.11 | 0.00-100.0% | 10.02 | 0.00 |
| Deferred Tax Assets | 1.05-40.3% | 1.76-26.1% | 2.38-24.9% | 3.17-15.9% | 3.77+2.7% | 3.67 | - | - |
| Other Assets | 0.71+12.7% | 0.63+1.6% | 0.62-1.6% | 0.63-27.6% | 0.87+128.9% | 0.38+100.0% | 0.19+5.6% | 0.18 |
| Total Assets | 89.58+24.7% | 71.85-53.3% | 153.90+2.7% | 149.86-37.3% | 239.14-11.1% | 268.97+83.6% | 146.52+36.0% | 107.73 |
| Short Term Debt Incl. Current Port. of LT Debt | 3.73+7.8% | 3.46+6.8% | 3.24+3.2% | 3.14+7.9% | 2.91+15.9% | 2.51+2.4% | 2.45+96.0% | 1.25 |
| Accounts Payable | 3.98+54.9% | 2.57+2.0% | 2.52-46.8% | 4.74+57.0% | 3.02-8.8% | 3.31-12.2% | 3.77+26.5% | 2.98 |
| Other Current Liabilities | 13.53-13.9% | 15.71-13.4% | 18.15-28.1% | 25.25-23.6% | 33.03+35.1% | 24.45+221.7% | 7.60+133.1% | 3.26 |
| Total Current Liabilities | 21.23-2.3% | 21.74-9.1% | 23.91-27.8% | 33.13-15.0% | 38.96+28.7% | 30.27+119.0% | 13.82+84.5% | 7.49 |
| Long Term Debt | 1.52-69.1% | 4.92-37.7% | 7.90-16.2% | 9.43-18.4% | 11.55+10.0% | 10.50-94.6% | 193.96+71.4% | 113.13 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 1.05-40.3% | 1.76-26.1% | 2.38-24.9% | 3.17-15.9% | 3.77+2.7% | 3.67 | - | - |
| Other Liabilities | 12.23-83.1% | 72.41+162.0% | 27.64+11917.4% | 0.23+76.9% | 0.13-97.1% | 4.49+23.7% | 3.63+322.1% | 0.86 |
| Total Liabilities | 36.04-64.3% | 100.82+63.1% | 61.82+34.5% | 45.96-15.5% | 54.41+11.2% | 48.93-76.9% | 211.41+74.0% | 121.48 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 53.55 | -28.97-131.5% | 92.08-11.4% | 103.90-43.8% | 184.73-16.0% | 220.04 | -64.89 | -13.75 |
| Total Shareholders Equity | 53.55 | -28.97-131.5% | 92.08-11.4% | 103.90-43.8% | 184.73-16.0% | 220.04 | -64.89 | -13.75 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 53.55 | -28.97-131.5% | 92.08-11.4% | 103.90-43.8% | 184.73-16.0% | 220.04 | -64.89 | -13.75 |
| Total Liabilities & Stockholders Equity | 89.58+24.7% | 71.85-53.3% | 153.90+2.7% | 149.86-37.3% | 239.14-11.1% | 268.97+83.6% | 146.52+36.0% | 107.73 |
| Book Value Per Share per share | 8.67 | -7.50-124.5% | 30.65-49.4% | 60.52-44.1% | 108.18-28.0% | 150.27 | -42.56 | -9.02 |
| Tangible Book Value Per Share per share | 8.67 | -7.50-124.5% | 30.65-49.4% | 60.52-44.1% | 108.18-28.0% | 150.27 | -42.56 | -9.02 |
| Full-Time Employees people | 82+17.1% | 70+6.1% | 66-20.5% | 83-10.8% | 93+25.7% | 74+21.3% | 61 | - |
| Price to Book Ratio ratio | 1.09 | 2.64 | 0.53 | 0.33 | 2.74 | 4.60 | -7.25 | - |
| Return on Assets % | -29.97 | -116.24 | -57.73 | -49.38 | -50.51 | -52.25 | -41.11 | - |
| Return on Equity % | -196.92 | -415.84 | -89.48 | -66.55 | -63.41 | -139.92 | - | - |
| Return on Invested Capital % | -43.93 | - | -87.70 | -84.75 | -65.38 | -47.08 | -40.49 | -14.02 |
| Quick Ratio ratio | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 |
| Current Ratio ratio | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -66.28 | -24.19 | -131.21 | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 | -13.93 |
| Depreciation | 1.11 | 0.93-64.5% | 2.62-14.7% | 3.07-16.3% | 3.67-2.9% | 3.78+13.5% | 3.33+44.8% | 2.30+78.3% | 1.29 |
| Other Funds (Non Cash) | -1.39 | -55.45-205.0% | 52.80+248.7% | 15.14+4.2% | 14.53+7.3% | 13.54-9.1% | 14.89 | -0.47-127.5% | 1.71 |
| Funds from Operations | -66.56 | -78.72 | -75.79 | -69.47 | -77.84 | -111.01 | -90.33 | -50.44 | -10.93 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -1.81 | -3.79 | -4.96 | -9.53 | -1.55 | -4.65-129.0% | 16.06+337.6% | 3.67-24.8% | 4.88 |
| Cash from Operating Activities | -68.37 | -82.50 | -80.74 | -79.00 | -79.39 | -115.66 | -74.26 | -46.77 | -6.05 |
| Capital Expenditures | -0.29 | -0.44 | -0.13 | -0.02 | -0.94 | -0.89 | -2.06 | -2.79 | -2.52 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 58.07 | -37.39 | -18.15-140.3% | 45.00 | -25.35-748.3% | 3.91-88.8% | 34.82+263.5% | 9.58 | -66.77 |
| Purchase of Investments | -39.43 | -164.89 | -108.15 | -0.01 | -104.27 | -19.09 | -45.28 | -70.42 | -66.77 |
| Sale Or Maturity of Investments | 97.50 | 127.50+41.7% | 90.00+100.0% | 45.01-43.0% | 78.92+243.1% | 23.00-71.3% | 80.10+0.1% | 80.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 57.78 | -37.83 | -18.28-140.6% | 44.98 | -26.29-970.5% | 3.02-90.8% | 32.76+382.5% | 6.79 | -69.29 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.36 | 101.65+23002.3% | 0.44-99.5% | 88.42+38343.5% | 0.23-99.7% | 78.76-59.1% | 192.41+124.8% | 85.58-14.3% | 99.89 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.36 | 101.65+23002.3% | 0.44-99.5% | 88.42+38343.5% | 0.23-99.7% | 78.76-59.1% | 192.41+124.8% | 85.58-14.3% | 99.89 |
| Proceedsfrom Stock Options | -100.98 | 0.30-31.8% | 0.44-99.5% | 88.40+44100.0% | 0.20-99.7% | 78.76-58.8% | 191.02+124.8% | 84.96-14.9% | 99.81 |
| Issuance or Reduction of Debt, Net | -0.09 | -0.01 | -0.08 | -0.10 | -0.06 | -0.08 | -0.06 | 0.00 | 0.00 |
| Change in Long Term Debt | -0.09 | -0.01 | -0.08 | -0.10 | -0.06 | -0.08 | -0.06 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -0.09 | -0.01 | -0.08 | -0.10 | -0.06 | -0.08 | -0.06 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | -0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | -0.00 |
| Cash from Financing Activities | 0.27 | 101.64+28940.0% | 0.35-99.6% | 88.33+55106.3% | 0.16-99.8% | 78.68-59.1% | 192.35+124.9% | 85.53-14.4% | 99.89 |
| Net Change in Cash | -10.32 | -18.69 | -98.67-281.7% | 54.31 | -105.52 | -33.96-122.5% | 150.84 | - | - |
| Free Cash Flow | -68.66 | -82.94 | -80.87 | -79.02 | -80.33 | -116.55 | -76.33 | -49.55 | -8.56 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 31.74-68.0% | 30.42-75.3% | 55.08-60.1% | 77.95+36.6% | 99.21+32.2% | 123.06+30.1% | 137.97+22.2% | 57.05-58.0% |
| Short Term Receivables | 0.00 | 27.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 2.94-30.5% | 3.93-19.6% | 4.55-13.0% | 4.91-3.5% | 4.23-11.7% | 4.89-1.4% | 5.23+2.3% | 5.09-4.1% |
| Total Current Assets | 34.68-66.5% | 62.13-51.4% | 59.63-58.4% | 82.86+33.3% | 103.44+29.6% | 127.94+28.5% | 143.21+21.3% | 62.14-56.0% |
| Net Property, Plant & Equipment | 12.24+117.8% | 3.44-43.8% | 4.17-39.2% | 4.96-32.3% | 5.62-29.5% | 6.12-28.9% | 6.86-25.5% | 7.33-25.4% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | - | - | - | 1.05-40.3% | - | - | - | 1.76-26.1% |
| Other Assets | 0.27-62.0% | 0.76+18.8% | 0.76+20.6% | 0.71+12.7% | 0.71+10.9% | 0.64+1.6% | 0.63+1.6% | 0.63+1.6% |
| Total Assets | 47.19-57.0% | 66.33-50.8% | 64.56-57.2% | 89.58+24.7% | 109.76+24.1% | 134.71+23.8% | 150.70+17.8% | 71.85-53.3% |
| Short Term Debt Incl. Current Port. of LT Debt | 1.24-65.2% | 3.22-9.0% | 3.69+5.7% | 3.73+7.8% | 3.56+4.7% | 3.54+5.7% | 3.49+6.7% | 3.46+6.8% |
| Accounts Payable | 3.21-31.0% | 6.43+63.2% | 7.64+71.3% | 3.98+54.9% | 4.65+69.7% | 3.94-42.2% | 4.46+57.0% | 2.57+2.0% |
| Other Current Liabilities | 15.15+10.0% | 18.70+46.2% | 11.99+9.0% | 13.53-13.9% | 13.77-7.1% | 12.79-4.5% | 11.00-13.8% | 15.71-13.4% |
| Total Current Liabilities | 19.60-10.9% | 28.34+39.8% | 23.32+23.1% | 21.23-2.3% | 21.99+4.9% | 20.27-14.0% | 18.95+0.4% | 21.74-9.1% |
| Long Term Debt | 10.66+326.4% | 0.29-91.3% | 0.66-85.0% | 1.52-69.1% | 2.50-56.4% | 3.34-48.5% | 4.39-39.1% | 4.92-37.7% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 1.05-40.3% | - | - | - | 1.76-26.1% |
| Other Liabilities | 5.62-58.2% | 5.81-37.1% | 8.79-19.5% | 12.23-83.1% | 13.44+15.5% | 9.24-19.9% | 10.92-74.0% | 72.41+162.0% |
| Total Liabilities | 35.88-5.4% | 34.44+4.9% | 32.77-4.3% | 36.04-64.3% | 37.93-1.0% | 32.84-21.0% | 34.25-49.7% | 100.82+63.1% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 11.31-84.3% | 31.88-68.7% | 31.79-72.7% | 53.55 | 71.83+43.4% | 101.87+51.5% | 116.44+94.7% | -28.97-131.5% |
| Total Shareholders Equity | 11.31-84.3% | 31.88-68.7% | 31.79-72.7% | 53.55 | 71.83+43.4% | 101.87+51.5% | 116.44+94.7% | -28.97-131.5% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 11.31-84.3% | 31.88-68.7% | 31.79-72.7% | 53.55 | 71.83+43.4% | 101.87+51.5% | 116.44+94.7% | -28.97-131.5% |
| Total Liabilities & Stockholders Equity | 47.19-57.0% | 66.33-50.8% | 64.56-57.2% | 89.58+24.7% | 109.76+24.1% | 134.71+23.8% | 150.70+17.8% | 71.85-53.3% |
| Book Value Per Share per share | 1.81-84.5% | 5.11-69.1% | 5.14-73.0% | 8.67 | 11.67-22.6% | 16.56-21.4% | 19.04-3.6% | -7.50-124.5% |
| Tangible Book Value Per Share per share | 1.81-84.5% | 5.11-69.1% | 5.14-73.0% | 8.67 | 11.67-22.6% | 16.56-21.4% | 19.04-3.6% | -7.50-124.5% |
| Full-Time Employees people | - | - | - | 82+17.1% | - | - | - | 70+6.1% |
| Price to Book Ratio ratio | 1.09 | 1.12 | 0.86 | 0.80 | 0.59 | 0.38 | -1.10 | 2.64 |
| Return on Assets % | -84.46 | -75.57 | -83.92 | -29.97 | -87.25 | -60.93 | -38.23 | -116.24 |
| Return on Equity % | -159.46 | -113.59 | -121.86 | -196.92 | -141.82 | -87.74 | -60.44 | -415.84 |
| Return on Invested Capital % | -99.52 | -4.67 | -71.01 | -36.10 | -42.43 | -15.08 | 35.66 | - |
| Quick Ratio ratio | 1.77 | 2.19 | 2.56 | 3.90 | 4.70 | 6.31 | 7.56 | 2.86 |
| Current Ratio ratio | 1.77 | 2.19 | 2.56 | 3.90 | 4.70 | 6.31 | 7.56 | 2.86 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -21.86 | -1.50 | -23.04-153.5% | -19.88 | -31.54 | -15.86-413.4% | 43.09 | -82.15 |
| Depreciation | 0.25+13.6% | 0.260.0% | 0.35+84.2% | 0.26-61.2% | 0.22-67.2% | 0.26-57.4% | 0.19-71.6% | 0.67-14.1% |
| Other Funds (Non Cash) | 1.52-72.1% | -1.21 | -1.99 | 0.29-99.5% | 5.44+225.7% | -0.83 | -60.36-456.3% | 63.47+1236.2% |
| Funds from Operations | -20.09 | -2.46 | -24.68 | -19.33 | -25.88 | -16.43 | -17.07 | -18.01 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 21.54+1307.8% | -22.49-2518.3% | 1.56 | -2.41 | 1.53 | 0.93-77.4% | -3.83 | -0.39 |
| Cash from Operating Activities | 1.45 | -24.95 | -23.13 | -21.75 | -24.34 | -15.50 | -20.91 | -18.40 |
| Capital Expenditures | -0.13 | -0.00 | -0.07 | -0.09 | -0.19 | -0.11 | -0.04 | -0.03 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00-100.0% | 25.00 | 35.00 | -1.93-109.7% | 47.88+359.5% | -39.31-198.3% | -44.02 | 20.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | -39.43 | -22.12 | -39.31 | -64.02 | 0.00 |
| Sale Or Maturity of Investments | 0.00-100.0% | 25.00 | 35.00+75.0% | 37.50+87.5% | 70.00+133.3% | 0.00-100.0% | 20.00 | 20.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.13-100.3% | 25.00 | 34.93 | -2.02-110.1% | 47.68+358.5% | -39.42-198.6% | -44.07 | 19.97 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00 | 0.24 | 0.00-100.0% | 0.13-7.1% | -0.04 | -0.18-160.0% | 101.74 | 0.14-99.8% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | 0.24 | 0.00-100.0% | 0.13-7.1% | -0.04 | -0.18-160.0% | 101.74 | 0.14-99.8% |
| Proceedsfrom Stock Options | 0.00 | 0.24 | 0.00-100.0% | -101.22-72400.0% | -0.04 | -0.18-160.0% | 101.74 | 0.14-99.8% |
| Issuance or Reduction of Debt, Net | -0.01 | -0.02 | -0.06 | -0.00 | -0.01 | -0.00 | 0.00 | -0.04 |
| Change in Long Term Debt | -0.01 | -0.02 | -0.06 | -0.00 | -0.01 | -0.00 | 0.00 | -0.04 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -0.01 | -0.02 | -0.06 | -0.00 | -0.01 | -0.00 | 0.00 | -0.04 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -0.01 | 0.22 | -0.06-100.1% | 0.12+20.0% | -0.05 | -0.18-164.3% | 101.74 | 0.10-99.9% |
| Net Change in Cash | 1.32-94.3% | 0.27 | 11.74-68.1% | -23.64-1515.6% | 23.29 | -55.10-365.2% | 36.77 | 1.67-97.4% |
| Free Cash Flow | 1.32 | -24.95 | -23.20 | -21.84 | -24.54 | -15.61 | -20.95 | -18.43 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Biological Products, (No Diagnostic Substances) | 3.61 | 2.19 | -39.5% | 100.0% |
| Total | 3.61 | 2.19 | -39.5% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 3.61 | 2.19 | -39.5% | 100.0% |
| Total | 3.61 | 2.19 | -39.5% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 13.96% | 0.7M | 4.9M | 71.98K |
| 2026-10-15 | 14.59% | 0.7M | 4.9M | 83.45K |
| 2026-09-30 | 14.61% | 0.7M | 4.9M | 160.42K |
| 2026-09-15 | 14.39% | 0.7M | 4.9M | 165.20K |
| 2026-08-31 | 13.37% | 0.6M | 4.9M | 172.75K |
| 2026-08-14 | 11.71% | 0.6M | 4.9M | 183.78K |
| 2026-07-31 | 12.51% | 0.6M | 4.9M | 174.48K |
| 2026-07-15 | 10.86% | 0.5M | 4.8M | 290.51K |
| 2026-06-30 | 11.32% | 0.5M | 4.8M | 213.92K |
| 2026-06-15 | 12.72% | 0.6M | 4.8M | 206.58K |
| 2026-05-29 | 11.99% | 0.6M | 4.8M | 199.69K |
| 2026-05-15 | 11.13% | 0.5M | 4.8M | 186.03K |
| 2026-04-30 | 10.18% | 0.5M | 4.8M | 170.17K |
| 2026-04-15 | 5.70% | 0.3M | 4.8M | 52.94K |
| 2026-03-31 | 6.34% | 0.3M | 4.8M | 55.33K |
| 2026-03-13 | 6.10% | 0.3M | 4.8M | 59.63K |
| 2026-02-27 | 6.04% | 0.3M | 4.8M | 64.54K |
| 2026-02-13 | 6.01% | 0.3M | 4.8M | 73.41K |
| 2026-01-30 | 6.12% | 0.3M | 4.8M | 77.54K |
| 2026-01-15 | 5.71% | 0.3M | 4.7M | 79.70K |
Option chain
expiry 2026-11-13| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-06 | 8-K | Current report | 2026-11-06 | SEC |
| 2026-09-15 | 8-K | Current report | 2026-09-10 | SEC |
| 2026-08-06 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-08-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-06 | 8-K | Current report | 2026-08-06 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-26 | 8-K | Current report | 2026-06-25 | SEC |
| 2026-06-24 | SCHEDULE 13D | SEC | ||
| 2026-05-15 | SCHEDULE 13G | SEC | ||
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-07 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-07 | 8-K | Current report | 2026-05-07 | SEC |
| 2026-04-29 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-04-29 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-04-29 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-25 | SEC |
| 2026-04-21 | 8-K | Current report | 2026-04-16 | SEC |
| 2026-04-14 | 8-K | Current report | 2026-04-14 | SEC |
| 2026-03-11 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-09 | SEC |
| 2026-03-11 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-09 | SEC |
| 2026-03-11 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-09 | SEC |
| 2026-03-11 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-09 | SEC |
| 2026-03-05 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-03-05 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2025-12-31 | SEC |
| 2026-03-05 | 8-K | Current report | 2026-03-05 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Deep Track Capital, LP | 7.18% |
| Alyeska Investment Group, L.P. | 6.66% |
| Sio Capital Management, LLC | 5.29% |
| MARSHALL WACE, LLP | 3.98% |
| Woodline Partners LP | 2.87% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.84% |
| BAKER BROS. ADVISORS LP | 1.34% |
| HHLR ADVISORS, LTD. | 1.23% |
| UBS Group AG | 1.08% |
| D. E. Shaw & Co., Inc. | 1.07% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.08% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.76% |
| Fidelity Extended Market Index Fund | 0.43% |
| iShares Micro-Cap ETF | 0.27% |
| U.S. MICRO CAP PORTFOLIO | 0.13% |
| Fidelity Total Market Index Fund | 0.12% |
| Fidelity Series Total Market Index Fund | 0.10% |
| U.S. SMALL CAP PORTFOLIO | 0.06% |
| Fidelity Nasdaq Composite Index Fund | 0.06% |
| Dimensional U.S. Small Cap ETF | 0.05% |
OakChart. ALGS. Cached 15 minutes. Terms
Some panels did not load: insider.